Company news

OBI Pharma, Inc. news in 2025

OBI Pharma, Inc.'s news releases, calls and decks from 2025, newest first.

View company

OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors

September 2, 2025

OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies

June 6, 2025

OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902, a Trop-2 Targeting ADC

April 30, 2025

OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and ThiOBI® ADC enabling technologies, the OBI-3424 prodrug, and Globo H (GH) science

April 22, 2025

OBI Pharma Receives ‘Most Promising ADC Clinical Candidate in Taiwan’ Award

March 12, 2025

Decks in 2025